Conference Coverage (ASCO)

Toxicities of Combination Immunotherapy for Neuroblastoma Are Manageable

Published in Cancer Weekly, July 13th, 1998

A phase I clinical trial of a chimeric human/murine anti-G_D2 monoclonal antibody (ch14.18) combined with granulocyte macrophage-colony stimulating factor (GM-CSF) for neuroblastoma in children defined the maximum tolerable dose (MTD) and range of toxicities.

M.F. Ozkaynak, representing colleagues from the New York Medical College, discussed the results of a children's cancer group study at the 34th Annual Meeting of the American Society of Clinical Oncology, held May 16-19, 1998, in Los Angeles, California (abstract "Phase I study of Chimeric Human/Murine Anti-G_D2 Monoclonal Antibody (ch14.18) with GM-CSF in Children with Neuroblastoma...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-07-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry